Share
Alessandro Bogliari, CEO and Co-Founder of The Influencer Marketing Factory, a global influencer marketing agency, talks with great guests about influencer marketing, social media, the creator economy, social commerce and much more.
…
continue reading
Manage episode 521478832 series 3299609
Content provided by Alice Watson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alice Watson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In Part 3, Hanna Svanbäck discusses the future of Alzheimer's care over the next five to 10 years, how trial design could be improved and reveals her opinion on the most exciting healthcare innovation on the horizon.
Speaker bio
Hanna Svanbäck is the Executive Director for Neuroscience, Eli Lilly, overseeing operations in the UK, Ireland and the Nordic countries. Hanna has over 15 years of experience at Lilly and is proud to lead the Neurosciences function given Lilly's long-standing commitment to advancing scientific innovation in this field. Hanna's passion for science and her dedication to utilising innovative approaches to enhance patient care are underpinned by her academic studies in Engineering Genomics and Biotechnology from the University of Umeå, Sweden and University of Manchester.
Follow us on Instagram: @emj.gold
316 episodes
))
